Cargando…

Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape

Real-time cell analysis (RTCA) enables high-throughput, quantitative kinetic measurements of cytopathic effect (CPE) in virus-infected cells. Here, we detail a RTCA approach for assessing antibody neutralization. We describe how to evaluate the neutralizing potency of monoclonal antibodies (mAbs) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suryadevara, Naveenchandra, Gilchuk, Pavlo, Zost, Seth J., Mittal, Nikhil, Zhao, Li Leyna, Crowe, James E., Carnahan, Robert H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023333/ https://www.ncbi.nlm.nih.gov/pubmed/35578733 http://dx.doi.org/10.1016/j.xpro.2022.101387

Ejemplares similares

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
por: Greaney, Allison J., et al.
Publicado: (2020)

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
por: Greaney, Allison J., et al.
Publicado: (2021)

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
por: Suryadevara, Naveenchandra, et al.
Publicado: (2021)

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
por: Chen, Elaine C., et al.
Publicado: (2021)

SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
por: Wall, Steven C., et al.
Publicado: (2023)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

Potently neutralizing and protective human antibodies against SARS-CoV-2
por: Zost, Seth J., et al.
Publicado: (2020)

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
por: Winkler, Emma S., et al.
Publicado: (2021)

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition
por: Kramer, Kevin J., et al.
Publicado: (2021)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
por: Diamond, Michael, et al.
Publicado: (2021)

Standardized two-step testing of antibody activity in COVID-19 convalescent plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
por: Dong, Jinhui, et al.
Publicado: (2021)

Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking
por: Shiakolas, Andrea R., et al.
Publicado: (2022)

Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
por: Chen, Elaine C., et al.
Publicado: (2023)

A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
por: Sievers, Benjamin Louis, et al.
Publicado: (2022)

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
por: Mousa, Jarrod J., et al.
Publicado: (2017)

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
por: Cobb, Ronald R., et al.
Publicado: (2022)

Searching for escape-resistant anti–SARS-CoV-2 neutralizing antibodies
por: Mahla, Ranjeet Singh, et al.
Publicado: (2022)

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
por: Cao, Yunlong, et al.
Publicado: (2021)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
por: Alenquer, Marta, et al.
Publicado: (2021)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2022)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2023)

Preventing escape from neutralizing antibodies
por: Brown, Matthew
Publicado: (2020)

Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
por: King, Liam B., et al.
Publicado: (2019)

A budding new approach strengthens an important message
por: Zost, Seth J., et al.
Publicado: (2023)

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
por: Diamond, Michael, et al.
Publicado: (2021)

Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and pre-emergent sarbecoviruses
por: Wang, Lin-Fa, et al.
Publicado: (2022)

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
por: Bangaru, Sandhya, et al.
Publicado: (2018)

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections
por: Gilchuk, Iuliia, et al.
Publicado: (2016)

Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants
por: Kuramochi, Taichi, et al.
Publicado: (2022)

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
por: Suryadevara, Naveenchandra, et al.
Publicado: (2022)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
por: Miersch, Shane, et al.
Publicado: (2021)

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
por: Zhao, Fangzhu, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system
por: Bukreyev, Alexander, et al.
Publicado: (2023)

Complete mapping of viral escape from neutralizing antibodies
por: Doud, Michael B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_67oov9c71h13nsuie061q6pqsb